<DOC>
	<DOCNO>NCT01564199</DOCNO>
	<brief_summary>The objective study assess extent charcoal prevents absorption salmeterol fluticasone via GI tract . The assessment base compare pharmacokinetic parameter area concentration-time curve ( AUCt ) .</brief_summary>
	<brief_title>Phase I Pharmacokinetic Study ( SALBLOCK )</brief_title>
	<detailed_description />
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Charcoal</mesh_term>
	<criteria>Healthy male female aged 1860 Normal weight least 50 kg Evidence clinically significant cardiovascular , renal , hepatic , haematological , gastrointestinal , pulmonary , metabolicendocrine , neurological psychiatric disease . Any condition require concomitant treatment ( include vitamin herbal product ) likely need concomitant treatment study . Any clinically significant abnormal laboratory value physical finding may interfere interpretation study result constitute health risk subject he/she participates study . Known hypersensitivity active substance ( ) excipients drug . Pregnant lactating female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>